This trial is active, not recruiting.

Condition malignant mesothelioma
Treatments recombinant interferon gamma, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, mitomycin c, conventional surgery, hyperthermia treatment, radiation therapy
Phase phase 2
Sponsor Herbert Irving Comprehensive Cancer Center
Collaborator National Cancer Institute (NCI)
Start date May 2001
Trial identifier NCT00024271, CDR0000068907, CPMC-IRB-13799, NCI-G01-2015


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs directly into the tumor after surgery and combining them with radiation therapy may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining surgery, chemotherapy, and radiation therapy in treating patients who have peritoneal cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Primary purpose treatment

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Histologically confirmed malignant mesothelioma - Measurable or evaluable disease - Ineligible for other high-priority study - No CNS metastases PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - SWOG 0-2 - Karnofsky 60-100% Life expectancy: - More than 2 months Hematopoietic: - WBC greater than 3,000/mm3 - Platelet count greater than 100,000/mm3 Hepatic: - Bilirubin less than 1.5 times normal Renal: - Creatinine clearance at least 45 mL/min - BUN less than 1.5 times normal - No significant calcium abnormalities Cardiovascular: - No symptomatic cardiovascular disease - No New York Heart Association class II, III, or IV heart disease - No congestive heart failure - No angina pectoris - No cardiac arrhythmia - No uncontrolled hypertension Other: - No significant phosphate, electrolyte, or other metabolic abnormalities (e.g., metabolic acidosis) - No uncontrolled psychiatric disorder or neurologic disease - No seizure disorder - No other malignancy within the past 5 years except curatively treated carcinoma in situ of the cervix or skin cancer - No other serious medical or psychiatric illness - No uncontrolled serious infection - No senility or emotional instability - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No more than 2 prior chemotherapy regimens - No more than 1 prior intraperitoneal chemotherapy regimen - More than 6 weeks since prior chemotherapy - No other concurrent chemotherapy Endocrine therapy: - No concurrent hormonal therapy except for nondisease-related conditions (e.g., insulin for diabetes) - Concurrent steroids for antiemesis, premedication, adrenal failure, or septic shock allowed Radiotherapy: - No prior abdominal, pelvic, or lower chest radiotherapy Surgery: - Prior surgical resection preceding disease recurrence allowed - More than 1 week since prior surgery

Additional Information

Official title Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma
Description OBJECTIVES: - Determine the response rate, duration of response, and duration of survival of patients with peritoneal mesothelioma treated with surgery, intraperitoneal chemotherapy, and whole abdominal radiotherapy. - Determine the toxicity of this regimen in these patients. OUTLINE: Patients undergo initial surgery, including total omentectomy and excision of gross disease. Approximately 3-4 weeks after surgery, patients receive intraperitoneal (IP) chemotherapy consisting of doxorubicin IP over 2 hours once weekly on weeks 1, 4, 7, and 10 and cisplatin IP and gemcitabine IP once weekly on weeks 2, 5, 8, and 11. Patients also receive interferon gamma IP once weekly on weeks 13-16. At approximately week 18-20, patients undergo second-look surgery. Patients with no gross disease receive hyperthermia mitomycin IP and cisplatin IP over 90 minutes. Approximately 2-4 weeks after second-look surgery, patients undergo radiotherapy 5 days a week for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, every 6 months for 3 years, and then annually for 5 years. PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in January 2014.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).